BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15386421)

  • 1. Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques.
    Jachimczak P; Apfel R; Bosserhoff AK; Fabel K; Hau P; Tschertner I; Wise P; Schlingensiepen KH; Schuler-Thurner B; Bogdahn U
    Int J Cancer; 2005 Jan; 113(1):88-92. PubMed ID: 15386421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
    Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
    Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
    Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inducing anti-tumor cytokines and an immune response in melanoma by inhibition of MIA using the peptide AR71.
    Riechers A; Schmidt J; Dettmer K; Oefner P; Jachimczak P; Schneider A; Bosserhoff AK
    Eur J Dermatol; 2013; 23(6):820-5. PubMed ID: 24413571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.
    Jachimczak P; Bogdahn U; Schneider J; Behl C; Meixensberger J; Apfel R; Dörries R; Schlingensiepen KH; Brysch W
    J Neurosurg; 1993 Jun; 78(6):944-51. PubMed ID: 8487077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.
    Hau P; Apfel R; Wiese P; Tschertner I; Blesch A; Bogdahn U
    Anticancer Res; 2002; 22(2A):577-83. PubMed ID: 12014625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity.
    Bosserhoff AK; Stoll R; Sleeman JP; Bataille F; Buettner R; Holak TA
    Lab Invest; 2003 Nov; 83(11):1583-94. PubMed ID: 14615412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of integrin activity by MIA.
    Bauer R; Humphries M; Fässler R; Winklmeier A; Craig SE; Bosserhoff AK
    J Biol Chem; 2006 Apr; 281(17):11669-77. PubMed ID: 16517605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
    Kasid A; Bell GI; Director EP
    J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning and characterization of the expression pattern of a novel splice product MIA (splice) of malignant melanoma-derived growth-inhibiting activity (MIA/CD-RAP) [corrected].
    Hau P; Wise P; Bosserhoff AK; Blesch A; Jachimczak P; Tschertner I; Bogdahn U; Apfel R
    J Invest Dermatol; 2002 Sep; 119(3):562-9. PubMed ID: 12230496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of melanoma inhibitory activity (MIA) expression in melanoma cells leads to molecular and phenotypic changes.
    Tatzel J; Poser I; Schroeder J; Bosserhoff AK
    Pigment Cell Res; 2005 Apr; 18(2):92-101. PubMed ID: 15760338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Culture medium induced morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells.
    Perng YP; Lin CC; Perng IM; Shen YC; Chuang CK; Liao SK
    Cancer Biother Radiopharm; 1997 Oct; 12(5):317-31. PubMed ID: 10851482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
    Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
    Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
    Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
    Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo.
    Guba M; Bosserhoff AK; Steinbauer M; Abels C; Anthuber M; Buettner R; Jauch KW
    Br J Cancer; 2000 Nov; 83(9):1216-22. PubMed ID: 11027436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.